The Oncology Care Model and Medicare Payments, Utilization, and Quality

Hey there, Medicare budget line items. Yeah, you - the ones labeled "cancer care spending." We need to talk.

For six years, the Centers for Medicare & Medicaid Services ran an experiment on you called the Oncology Care Model (OCM), and the results are in. Spoiler alert: it's complicated. Like "we saved money but also lost money" complicated. I know, I know - only the federal government could pull off that particular magic trick.

What Was This Whole OCM Thing Anyway?

Back in 2016, someone at CMS had a reasonable thought: "What if we paid cancer doctors differently and they delivered better, cheaper care?" The OCM was born - an alternative payment model where oncology practices could earn bonuses for keeping costs down and quality up during chemotherapy treatment.

The idea wasn't crazy. Cancer care is expensive (understatement of the century), and the traditional fee-for-service model basically rewards doing more stuff rather than doing the right stuff. The OCM tried to flip that script by bundling payments into six-month "episodes" and giving practices financial incentives to be efficient.

The Study: A Numbers Game with Real Stakes

A team of researchers led by Gabriel Brooks recently published their evaluation in JAMA, and they didn't mess around [1]. They analyzed nearly 3.7 million chemotherapy episodes from over 1.5 million Medicare beneficiaries. That's not a pilot study - that's basically watching the entire system in action.

They compared 202 practices that voluntarily joined the OCM against 534 similar practices that didn't. The methodology was solid: difference-in-differences analysis with propensity matching, which is statistics-speak for "we tried really hard to make sure we were comparing apples to apples."

The Good News (Sort Of)

Here's where it gets interesting. Total episode payments dropped by $616 per episode in OCM practices compared to the control group. Not exactly pennies - multiply that across hundreds of thousands of episodes and you're talking real money.

Even better, the savings grew over time. By the final six months of the program, OCM practices were saving $1,282 per episode. That's the kind of trend line that makes policy wonks excited. The savings came primarily from Part A (hospital stuff) and Part B (outpatient services), suggesting practices were actually changing how they delivered care.

And here's the part that matters most: quality didn't suffer. Hospitalization rates, emergency department visits, and other quality measures stayed essentially the same. Nobody was cutting corners at patients' expense.

The "Well, Actually" Part

Now for the twist that nobody at CMS wanted to hear.

To make the OCM work, Medicare paid practices extra money each month - $160 per beneficiary for "enhanced oncology services." They also paid out performance bonuses when practices hit their targets. Reasonable, right? You want behavior change, you pay for it.

The problem: those payments added up to more than the savings. A lot more.

When you tally everything up - the $616 saved per episode minus the enhanced services payments minus the performance bonuses - Medicare lost an estimated $639 million over six years. That's not a rounding error. That's a lot of chemotherapy.

What This Actually Means

Before we declare the OCM a failure and move on, let's pump the brakes. A few things worth noting:

First, the savings were accelerating. If the program had continued, those growing per-episode reductions might have eventually outpaced the fixed payments. We'll never know because it ended in 2022.

Second, the practices that joined were volunteers. They were probably already pretty good at this stuff. The comparison practices might have been improving too, just following the leaders. That would make the OCM's true impact look smaller than it was.

Third, healthcare transformation is hard and slow. Six years sounds like a long time, but changing how oncology practices operate - their workflows, their culture, their decision-making - doesn't happen overnight. Several studies have shown that alternative payment models often need extended timeframes to demonstrate their full potential [2,3].

The Bigger Picture

The OCM has been replaced by the Enhancing Oncology Model (EOM), which launched in 2023. CMS clearly learned some lessons - the new model has lower enhanced payments and different quality requirements.

But here's the uncomfortable truth that this study highlights: paying doctors to do better doesn't automatically mean they'll do better enough to offset what you're paying them. The incentives have to be calibrated just right. Too little, and nobody changes behavior. Too much, and you're just subsidizing the status quo.

Cancer care remains absurdly expensive, and it's only getting more so as new treatments (especially immunotherapies and targeted agents) enter the market. Finding ways to deliver high-quality care without bankrupting Medicare is one of the defining healthcare challenges of our time.

The OCM showed that practices can reduce spending without harming patients. That's not nothing. But it also showed that the math has to actually math.

Sometimes the most honest conclusion is: "Nice try. Keep trying."

References

1. Brooks GA, Trombley M, McClellan S, et al. The Oncology Care Model and Medicare Payments, Utilization, and Quality. JAMA. 2026. doi:10.1001/jama.2026.2075

2. Newcomer LN, Gould B, Page RD, Donelan SA, Perkins M. Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract. 2014;10(5):322-326. doi:10.1200/JOP.2014.001488

3. Gondi S, Song Z. Potential Implications of Private Equity Investments in Health Care Delivery. JAMA. 2019;321(11):1047-1048. doi:10.1001/jama.2019.1077

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.